DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma

NCT03837873 PHASE2 UNKNOWN

Patients eligible for the study will receive R-DA-EDOCH as the induction therapy and be evaluated by PET CT after the fourth cycle. Patients achieve CR at interim-PET(Deauville score 1-3) will receive either ASCT or the remaining 4 cycles of R-DA-EDOCH, while those achieve PR(Deauville score 4-5) will be rescued by two courses of R(2)-DHAP and then be revaluated by the second interim-PET. Patients who achieved CR+good PR(Deauville score 4) after the rescue therapy will be consolidated with ASCT,and those remain in PR(Deauville score 5) will receive other rescue treatments(including ASCT+CAR T).

Details

Lead sponsor	Institute of Hematology & Blood Diseases Hospital, China
Phase	PHASE2
Status	UNKNOWN
Enrolment	118
Start date	Mon Jan 21 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Sep 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Diffuse Large B Cell Lymphoma
• High-grade B-cell Lymphoma
• Transformed Lymphoma

Interventions

• Rituximab
• Etoposide
• Vincristine
• Doxorubicin
• Dexamethasone
• Cyclophosphamide
• Lenalidomide
• Cisplatin
• Cytarabine

Countries

China